Joseph Stringer
Stock Analyst at Needham
(4.39)
# 332
Out of 5,147 analysts
299
Total ratings
48.23%
Success rate
21.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $90 → $103 | $81.15 | +26.93% | 26 | Feb 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $148 → $139 | $92.73 | +49.90% | 30 | Feb 26, 2026 | |
| VIR Vir Biotechnology | Maintains: Buy | $14 → $18 | $9.09 | +98.02% | 20 | Feb 24, 2026 | |
| GILD Gilead Sciences | Reiterates: Buy | $170 | $148.95 | +14.13% | 11 | Feb 23, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $529 → $510 | $332.92 | +53.19% | 25 | Feb 12, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $29 → $28 | $20.96 | +33.59% | 21 | Jan 13, 2026 | |
| PCVX Vaxcyte | Maintains: Buy | $90 → $110 | $61.74 | +78.17% | 18 | Jan 7, 2026 | |
| MRNA Moderna | Reiterates: Hold | n/a | $53.57 | - | 9 | Oct 20, 2025 | |
| STOK Stoke Therapeutics | Maintains: Buy | $22 → $35 | $36.41 | -3.87% | 24 | Oct 10, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 | $12.56 | +122.93% | 52 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $11 | $5.60 | +96.43% | 19 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $496.83 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.47 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.30 | +669.23% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $24.56 | +50.65% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $18.25 | -1.37% | 2 | Aug 24, 2021 |
Ionis Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $90 → $103
Current: $81.15
Upside: +26.93%
Rhythm Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $148 → $139
Current: $92.73
Upside: +49.90%
Vir Biotechnology
Feb 24, 2026
Maintains: Buy
Price Target: $14 → $18
Current: $9.09
Upside: +98.02%
Gilead Sciences
Feb 23, 2026
Reiterates: Buy
Price Target: $170
Current: $148.95
Upside: +14.13%
Alnylam Pharmaceuticals
Feb 12, 2026
Maintains: Buy
Price Target: $529 → $510
Current: $332.92
Upside: +53.19%
Apellis Pharmaceuticals
Jan 13, 2026
Maintains: Buy
Price Target: $29 → $28
Current: $20.96
Upside: +33.59%
Vaxcyte
Jan 7, 2026
Maintains: Buy
Price Target: $90 → $110
Current: $61.74
Upside: +78.17%
Moderna
Oct 20, 2025
Reiterates: Hold
Price Target: n/a
Current: $53.57
Upside: -
Stoke Therapeutics
Oct 10, 2025
Maintains: Buy
Price Target: $22 → $35
Current: $36.41
Upside: -3.87%
Phathom Pharmaceuticals
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $12.56
Upside: +122.93%
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $5.60
Upside: +96.43%
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $496.83
Upside: -
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.47
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.30
Upside: +669.23%
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $24.56
Upside: +50.65%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $18.25
Upside: -1.37%